Who are Epiduo/Tactuo's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Adapalene + benzoyl peroxide samples, Adapalene/benzoyl peroxide gel, 0.1%/2.5%, Epiduo® Gel right face, BENZOYL PEROXIDE/ ADAPALENE, Adapalene-BPO Gel, adapalene/benzoyl peroxide.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/epiduo-tactuo.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Epiduo/Tactuo — Competitive Intelligence Brief

Epiduo/Tactuo (Epiduo/Tactuo) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Retinoid + peroxide combination. Area: Dermatology.

phase 3 Retinoid + peroxide combination Retinoic acid receptor (adapalene); bacterial cell membrane disruption (benzoyl peroxide) Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

Epiduo/Tactuo (Epiduo/Tactuo) — Galderma R&D. Epiduo/Tactuo combines adapalene (a retinoid) and benzoyl peroxide to reduce acne by normalizing skin cell turnover and killing acne-causing bacteria.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Epiduo/Tactuo TARGET	Epiduo/Tactuo	Galderma R&D	phase 3	Retinoid + peroxide combination	Retinoic acid receptor (adapalene); bacterial cell membrane disruption (benzoyl peroxide)
Adapalene + benzoyl peroxide samples	Adapalene + benzoyl peroxide samples	Wake Forest University	marketed	Retinoid + peroxide combination	Retinoic acid receptors (adapalene); bacterial cell membrane and proteins (benzoyl peroxide)
Adapalene/benzoyl peroxide gel, 0.1%/2.5%	Adapalene/benzoyl peroxide gel, 0.1%/2.5%	Galderma R&D	marketed	Retinoid + peroxide combination	Retinoic acid receptors (adapalene); bacterial cell membrane and proteins (benzoyl peroxide)
Epiduo® Gel right face	Epiduo® Gel right face	GWT-TUD GmbH	marketed	Retinoid + peroxide combination	Retinoic acid receptor (adapalene); bacterial cell membrane disruption (benzoyl peroxide)
BENZOYL PEROXIDE/ ADAPALENE	BENZOYL PEROXIDE/ ADAPALENE	Stiefel, a GSK Company	marketed	Retinoid + peroxide combination	Retinoic acid receptors (adapalene); bacterial cell oxidative stress (benzoyl peroxide)
Adapalene-BPO Gel	Adapalene-BPO Gel	Galderma Brasil Ltda.	marketed	Retinoid + peroxide combination	Retinoic acid receptors (adapalene); bacterial cell membrane and proteins (benzoyl peroxide)
adapalene/benzoyl peroxide	adapalene/benzoyl peroxide	Galderma R&D	marketed	Retinoid + peroxide combination	Retinoic acid receptors (adapalene); bacterial cell membrane and proteins (benzoyl peroxide)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Retinoid + peroxide combination class)

Galderma R&D · 5 drugs in this class
GWT-TUD GmbH · 1 drug in this class
Galderma Brasil Ltda. · 1 drug in this class
Derm Research, PLLC · 1 drug in this class
Padagis LLC · 1 drug in this class
Stiefel, a GSK Company · 1 drug in this class
Wake Forest University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Epiduo/Tactuo — Competitive Intelligence Brief. https://druglandscape.com/ci/epiduo-tactuo. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab